Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON PEN versus BYETTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON PEN versus BYETTA.
BYDUREON PEN vs BYETTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon secretion, slows gastric emptying, and promotes satiety.
2 mg subcutaneously once every 7 days (weekly)
5 mcg subcutaneously twice daily within 60 minutes before morning and evening meals; may increase to 10 mcg twice daily after 1 month if tolerated.
None Documented
None Documented
Terminal elimination half-life is 2.4 hours following subcutaneous administration; due to extended-release microspheres, systemic exposure is sustained over 10 weeks with multiple dosing (effective half-life ~2 weeks).
Terminal elimination half-life 2.4 hours; provides clinical duration of action supporting twice-daily dosing.
Renal excretion of intact exenatide via glomerular filtration and proteolytic degradation; approximately 100% of administered dose eliminated via renal pathways (urine) as intact peptide and metabolites.
Primarily renal; intact drug eliminated in urine (approximately 80% of the dose). Minor biliary/fecal excretion accounts for <10%.
Category C
Category C
Antidiabetic
Antidiabetic